Thrombophilia classification: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 11: | Line 11: | ||
:*Acquired thrombophilia or secondary hypercoagulable state | :*Acquired thrombophilia or secondary hypercoagulable state | ||
:*Mixed/Unknown | :*Mixed/Unknown | ||
*Different thrombophilic states are associated with venous or both venous and arterial clots | *Different thrombophilic states are associated with venous or both venous and arterial clots. | ||
{| class="wikitable" | {| class="wikitable" | ||
Revision as of 03:46, 2 July 2016
|
Thrombophilia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Thrombophilia classification On the Web |
|
American Roentgen Ray Society Images of Thrombophilia classification |
|
Risk calculators and risk factors for Thrombophilia classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Asiri Ediriwickrema, M.D., M.H.S. [2]
Overview
Thrombophilias are classified as either inherited or a primary hypercoagulable state, acquired or a secondary hypercoagulable state, or mixed/unknown. Certain conditions are associated with greater thrombotic risks and both venous and arterial clots.
Classification
- Inherited thrombophilia or primary hypercoagulable state
- Acquired thrombophilia or secondary hypercoagulable state
- Mixed/Unknown
- Different thrombophilic states are associated with venous or both venous and arterial clots.
| Thrombophilia Classification | ||
|---|---|---|
| Inherited (Primary) | Acquired (Secondary) | Mixed/Unknown |
| Activated protein C (APC) resistance (Factor V Leiden) | Age | Hyperhomocysteinemia |
| Prothrombin gene mutation (Prothrombin G20210A) | Immobilization | APC resistance unrelated to Factor V Leiden. |
| Antithrombin deficiency | Trauma/major surgery | Increased factor VIII levels |
| Protein C and protein S deficiency | Orthopedic surgery | Increased factor XI levels |
| Dysfibrinogenemia | Malignancy | Increased factor IX levels |
| Non-O blood type | Myeloproliferative disorders (polycythemia vera, essential thrombocythemia, hyperviscosity) | Increased levels of thrombin-activatable fibrinolysis inhibitor (TAFI) |
| Pregnancy | Decreased levels of free tissue factor pathway inhibitor (TFPI) | |
| Estrogen and testosterone (oral contraceptives, hormone replacement therapy, and selective estrogen receptor modulator) | ||
| Obesity | ||
| Heart Failure | ||
| Cirrhosis | ||
| Chronic renal disease (nephrotic syndrome) | ||
| Antiphospholipid syndrome (APLS) or lupus anticoagulant | ||
| Heparin induced thrombocytopenia (HIT) | ||
| Disseminated intravascular coagulopathy (DIC) | ||
| Paroxysmal nocturnal hemoglobinuria (PNH) | ||
| Autoimmune disorders (Vasculitis, celiac's disease, inflammatory bowel disease) | ||
| Thrombotic microangiopathy | ||
| Sickle cell disease | ||
| Drug related (chemotherapies including L-aspariginase, mitomycin; infusion of clotting factors including prothrombin complex concentrates, cryoprecipitate; drugs including hydralazine, procainamide, or phenothiazines can promote lupus anticoagulant formation) | ||
| Thrombophilic states associated with arterial clots |
|---|
| APLS and lupus anticoagulant |
| HIT |
| DIC |
| PNH |
| Cold agglutinins (associated with mycoplasma infections) |
| Vasculitis |
| Hyperhomocysteinemia |
References
- ↑ Hoffman R, Benz EJ, Shattil SJ, et al. Hematology: Basic Principles and Practice: Elsevier Science Health Science Division; 2004.
- ↑ Cohoon KP, Heit JA (2014). "Inherited and secondary thrombophilia". Circulation. 129 (2): 254–7. doi:10.1161/CIRCULATIONAHA.113.001943. PMC 3979345. PMID 24421360.